$EGRX
EAGLE PHARMACEUTICALS, INC.

2016 Q2 Form 10-Q Financial Statement

#000082787116000074 Filed on August 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2
Revenue $40.92M $6.002M
YoY Change 581.74% 3.63%
Cost Of Revenue $11.47M $3.348M
YoY Change 242.68% 115.17%
Gross Profit $29.45M $2.654M
YoY Change 1009.46% -37.35%
Gross Profit Margin 71.96% 44.22%
Selling, General & Admin $11.99M $5.111M
YoY Change 134.59% 91.21%
% of Gross Profit 40.72% 192.58%
Research & Development $3.799M $5.878M
YoY Change -35.37% 29.33%
% of Gross Profit 12.9% 221.48%
Depreciation & Amortization $320.0K $10.00K
YoY Change 3100.0% -50.0%
% of Gross Profit 1.09% 0.38%
Operating Expenses $27.26M $14.34M
YoY Change 90.15% 63.4%
Operating Profit $13.66M -$8.335M
YoY Change -263.84% 179.51%
Interest Expense $3.000K $3.000K
YoY Change 0.0% -40.0%
% of Operating Profit 0.02%
Other Income/Expense, Net $27.00K $5.000K
YoY Change 440.0% -89.58%
Pretax Income $13.68M -$8.330M
YoY Change -264.26% 183.91%
Income Tax $584.0K -$153.0K
% Of Pretax Income 4.27%
Net Earnings $13.10M -$8.177M
YoY Change -260.19% 178.7%
Net Earnings / Revenue 32.01% -136.24%
Basic Earnings Per Share $0.84 -$0.53
Diluted Earnings Per Share $0.80 -$0.53
COMMON SHARES
Basic Shares Outstanding 15.64M shares 15.55M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.60M $103.7M
YoY Change -27.1% 108.23%
Cash & Equivalents $75.56M $13.69M
Short-Term Investments $90.00M
Other Short-Term Assets $328.0K $198.0K
YoY Change 65.66% -51.56%
Inventory $6.363M $2.325M
Prepaid Expenses
Receivables $52.03M $12.98M
Other Receivables $0.00 $0.00
Total Short-Term Assets $135.5M $120.6M
YoY Change 12.4% 108.73%
LONG-TERM ASSETS
Property, Plant & Equipment $2.813M $374.0K
YoY Change 652.14% 4.03%
Goodwill
YoY Change
Intangibles $10.96M
YoY Change
Long-Term Investments
YoY Change
Other Assets $94.00K $104.0K
YoY Change -9.62% 131.11%
Total Long-Term Assets $13.87M $478.0K
YoY Change 2801.05% 18.17%
TOTAL ASSETS
Total Short-Term Assets $135.5M $120.6M
Total Long-Term Assets $13.87M $478.0K
Total Assets $149.4M $121.0M
YoY Change 23.41% 108.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.43M $4.783M
YoY Change 138.99% 89.76%
Accrued Expenses $23.34M $13.54M
YoY Change 72.37% 81.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.78M $24.58M
YoY Change 45.56% 51.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.800M
YoY Change
Total Long-Term Liabilities $5.800M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $35.78M $24.58M
Total Long-Term Liabilities $5.800M $0.00
Total Liabilities $41.50M $24.60M
YoY Change 68.7% 51.85%
SHAREHOLDERS EQUITY
Retained Earnings -$94.91M -$98.16M
YoY Change -3.31% 3.25%
Common Stock $15.00K $15.00K
YoY Change 0.0% 6.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $107.8M $96.45M
YoY Change
Total Liabilities & Shareholders Equity $149.4M $121.0M
YoY Change 23.41% 108.1%

Cashflow Statement

Concept 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income $13.10M -$8.177M
YoY Change -260.19% 178.7%
Depreciation, Depletion And Amortization $320.0K $10.00K
YoY Change 3100.0% -50.0%
Cash From Operating Activities -$2.630M -$12.12M
YoY Change -78.3% 160.09%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$290.0K
YoY Change -65.52% 2800.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$74.00M
YoY Change -100.0%
Cash From Investing Activities -$100.0K -$74.29M
YoY Change -99.87% 742800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 170.0K
YoY Change -100.0% -140.48%
NET CHANGE
Cash From Operating Activities -2.630M -12.12M
Cash From Investing Activities -100.0K -74.29M
Cash From Financing Activities 0.000 170.0K
Net Change In Cash -2.730M -86.24M
YoY Change -96.83% 1594.3%
FREE CASH FLOW
Cash From Operating Activities -$2.630M -$12.12M
Capital Expenditures -$100.0K -$290.0K
Free Cash Flow -$2.530M -$11.83M
YoY Change -78.61% 154.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000827871
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15636387 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
EAGLE PHARMACEUTICALS, INC.
CY2015Q4 egrx Accrued Product Costs Current
AccruedProductCostsCurrent
9232000 USD
CY2016Q2 egrx Accrued Product Costs Current
AccruedProductCostsCurrent
4955000 USD
CY2015Q4 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
1784000 USD
CY2016Q2 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
2047000 USD
egrx Accrued Stock Issuance Costs
AccruedStockIssuanceCosts
0 USD
egrx Accrued Stock Issuance Costs
AccruedStockIssuanceCosts
0 USD
egrx Income Taxes Paid Franchise Taxes Paid
IncomeTaxesPaidFranchiseTaxesPaid
78000 USD
egrx Income Taxes Paid Franchise Taxes Paid
IncomeTaxesPaidFranchiseTaxesPaid
107000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
-81000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
-319000 USD
CY2016Q2 egrx Number Of Products
NumberOfProducts
5 product
egrx Numberof Sales Representatives Hired
NumberofSalesRepresentativesHired
12 person
CY2015Q4 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
551000 USD
CY2016Q2 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
190000 USD
CY2015Q4 egrx Prepaid Product Costs
PrepaidProductCosts
85000 USD
CY2016Q2 egrx Prepaid Product Costs
PrepaidProductCosts
439000 USD
CY2015Q4 egrx Prepaid Research And Development
PrepaidResearchAndDevelopment
283000 USD
CY2016Q2 egrx Prepaid Research And Development
PrepaidResearchAndDevelopment
9000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3857000 USD
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
11431000 USD
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26267000 USD
CY2016Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
52027000 USD
CY2015Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 USD
CY2016Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
221000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24405000 USD
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23336000 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
792000 USD
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1471000 USD
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2242000 USD
CY2016Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2382000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
197440000 USD
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
202729000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5289000 USD
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1209000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1593000 USD
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2420000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5289000 USD
CY2015Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2016Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
156000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
260000 USD
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1836327 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1556815 shares
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1448172 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1359519 shares
CY2015Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2016Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2015Q4 us-gaap Assets
Assets
124605000 USD
CY2016Q2 us-gaap Assets
Assets
149366000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
122257000 USD
CY2016Q2 us-gaap Assets Current
AssetsCurrent
135499000 USD
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
0 USD
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
6370000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
395000 USD
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 USD
CY2016Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1012000 USD
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 USD
CY2016Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5753000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34869000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13686000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79083000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75563000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21183000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3520000 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15636387 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15636387 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15636387 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15636387 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
15000 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
15000 USD
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
3348000 USD
us-gaap Cost Of Revenue
CostOfRevenue
9296000 USD
CY2016Q2 us-gaap Cost Of Revenue
CostOfRevenue
11473000 USD
us-gaap Cost Of Revenue
CostOfRevenue
26062000 USD
CY2015Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
521000 USD
CY2016Q2 us-gaap Deferred Rent Credit
DeferredRentCredit
507000 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6000000 USD
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
us-gaap Depreciation
Depreciation
22000 USD
us-gaap Depreciation
Depreciation
296000 USD
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.77
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P18Y
CY2015Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
0 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
260000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
8156000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
312000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
623000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
623000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
623000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
623000 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
0 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11220000 USD
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10960000 USD
CY2015Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2016Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1750000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-273000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8330000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11766000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13683000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12805000 USD
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-153000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
246000 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
584000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
603000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
187000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1282000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7574000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1026000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
25760000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1373000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1069000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-260000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1083000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-8679000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
59000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-49000 USD
CY2015Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
975899 shares
CY2016Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
829633 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
890209 shares
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 USD
CY2016Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10960000 USD
CY2015Q2 us-gaap Interest Expense
InterestExpense
3000 USD
us-gaap Interest Expense
InterestExpense
4000 USD
CY2016Q2 us-gaap Interest Expense
InterestExpense
3000 USD
us-gaap Interest Expense
InterestExpense
4000 USD
us-gaap Interest Paid
InterestPaid
4000 USD
us-gaap Interest Paid
InterestPaid
1000 USD
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
311000 USD
CY2016Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
845000 USD
CY2015Q4 us-gaap Inventory Net
InventoryNet
15042000 USD
CY2016Q2 us-gaap Inventory Net
InventoryNet
6363000 USD
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
8687000 USD
CY2016Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
5518000 USD
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
6044000 USD
CY2016Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2016Q2 us-gaap Inventory Write Down
InventoryWriteDown
1700000 USD
us-gaap Inventory Write Down
InventoryWriteDown
1700000 USD
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
15000 USD
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
30000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
51000 USD
CY2015Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
95000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
163000 USD
CY2016Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
156000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
318000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124605000 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149366000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34262000 USD
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
35779000 USD
CY2016Q1 us-gaap Loss Contingency Patents Allegedly Infringed Number
LossContingencyPatentsAllegedlyInfringedNumber
2 patent
CY2015Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1612000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2571000 USD
CY2016Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3318000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
5721000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55427000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90326000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4004000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13716000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
484000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-8177000 USD
us-gaap Net Income Loss
NetIncomeLoss
11520000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
13099000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Net Income Loss
NetIncomeLoss
12202000 USD
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8177000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
11520000 USD
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
13099000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
12202000 USD
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8177000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
11520000 USD
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
13099000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
12202000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
27000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
47000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
14337000 USD
us-gaap Operating Expenses
OperatingExpenses
30556000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
27262000 USD
us-gaap Operating Expenses
OperatingExpenses
57750000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8335000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
11755000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
13656000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
12758000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2255000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
281000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
564000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
564000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
564000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
282000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 USD
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
286000 USD
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
220000 USD
CY2016Q2 us-gaap Other Assets Current
OtherAssetsCurrent
328000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
143000 USD
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
94000 USD
CY2015Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
30000000 USD
CY2016Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
6000000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
4850000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
327000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
904000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
89999000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
62000000 USD
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1865000 USD
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1546000 USD
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
218000 USD
CY2016Q2 us-gaap Prepaid Insurance
PrepaidInsurance
454000 USD
CY2015Q4 us-gaap Prepaid Taxes
PrepaidTaxes
508000 USD
CY2016Q2 us-gaap Prepaid Taxes
PrepaidTaxes
126000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
6500000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
54331000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
0 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
62000000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1750000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1096000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2205000 USD
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2813000 USD
CY2016Q2 us-gaap Purchase Obligation
PurchaseObligation
16128000 USD
CY2016Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
16128000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5878000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12163000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3729000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10405000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107112000 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94910000 USD
CY2015Q2 us-gaap Royalty Revenue
RoyaltyRevenue
2272000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
5525000 USD
CY2016Q2 us-gaap Royalty Revenue
RoyaltyRevenue
31311000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
40779000 USD
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3730000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6786000 USD
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
9607000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
23729000 USD
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
6002000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
42311000 USD
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
40918000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
70508000 USD
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5111000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9097000 USD
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12060000 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23033000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1593000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5289000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3033
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3156
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3131
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0209
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0209
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0190
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0142
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0142
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0129
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0129
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
90343000 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
107834000 USD
CY2015Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15546796 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15876397 shares
CY2016Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16466020 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16526596 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15546796 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14900498 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15636387 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15636387 shares
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made.&#160;Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and related notes included in our annual report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC on February 29, 2016.</font></div></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name View Source Status
0000827871-16-000074-index-headers.html Edgar Link pending
0000827871-16-000074-index.html Edgar Link pending
0000827871-16-000074.txt Edgar Link pending
0000827871-16-000074-xbrl.zip Edgar Link pending
egrx-20160630.xml Edgar Link completed
egrx-20160630.xsd Edgar Link pending
egrx-20160630_cal.xml Edgar Link unprocessable
egrx-20160630_def.xml Edgar Link unprocessable
egrx-20160630_lab.xml Edgar Link unprocessable
egrx-20160630_pre.xml Edgar Link unprocessable
egrx_q2x2016.htm Edgar Link pending
exhibit311q22016.htm Edgar Link pending
exhibit312q22016.htm Edgar Link pending
exhibit321q22016.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending